GLP-1 receptor agonists may aid smoking cessation by curbing cravings and mitigating weight gain, which often are impediments ...

Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for ...

As Australia faces a turning point in obesity management, researchers from Monash University have contributed new insights ...

For adults with diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with a reduced ...

For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased risk for psychiatric adverse events or worsening ...

For people trying to quit smoking, use of a GLP-1 receptor agonist may help prevent weight gain, a common barrier to quitting, researchers said here. In a systematic review and meta-analysis of three ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and obesity.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant ... exenatide (Byetta or Bydureon), and dulaglutide (Trulicity). The analysis found that treatment with GLP-1RAs ...

Data were included for 262 adults with a body mass index greater than or equal to 27kg/m2 who were initiated on liraglutide or semaglutide. HealthDay News — Glucagon-like peptide-1 receptor ...

THURSDAY, May 15, 2025 (HealthDay News) -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and obesity ...